Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

1.870 +0.140 (+8.09%)
Streaming Delayed Price Updated: 10:46 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Corvus Pharma Com

< Previous 1 2 Next >
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad... 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
Via FinancialNewsMedia
Exposures COVID-19
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.